2012
SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2- metastatic breast cancer (MBC).
Mayer I, Abramson V, Balko J, Isakoff S, Kuba M, Sanders M, Forero-Torres A, Yap J, Van Den Abbeele A, Li Y, Arteaga C, Winer E. SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2- metastatic breast cancer (MBC). Journal Of Clinical Oncology 2012, 30: 510-510. DOI: 10.1200/jco.2012.30.15_suppl.510.Peer-Reviewed Original ResearchMetastatic breast cancerPan-PI3K inhibitor BKM120FDG-PETArm API3K pathway alterationsPhase Ib studyPhase Ib trialPost-menopausal patientsPI3K pathway inhibitionPI3K mutationsPI3K inhibitorsIb trialStable diseaseVisceral metastasesUnacceptable toxicityMost patientsArm BMedian ageDisease progressionPharmacodynamic biomarkersBreast cancerTreatment responseTumor biopsiesAntiestrogen resistanceIb study
2011
P2-09-07: Metabolic Response by FDG-PET in Patients (pts) Receiving Trastuzumab (T) and Lapatinib (L) for HER2+ Metastatic Breast Cancer (MBC): Correlative Analysis of TBCRC 003.
Yap J, Locascio T, Najita J, Mayer I, Hobday T, Falkson C, Dees E, Gelman R, Rimawi M, Nanda R, Berkowitz J, Franchetti Y, Wolff A, Winer E, Lin N, Van den Abbeele A. P2-09-07: Metabolic Response by FDG-PET in Patients (pts) Receiving Trastuzumab (T) and Lapatinib (L) for HER2+ Metastatic Breast Cancer (MBC): Correlative Analysis of TBCRC 003. Cancer Research 2011, 71: p2-09-07-p2-09-07. DOI: 10.1158/0008-5472.sabcs11-p2-09-07.Peer-Reviewed Original ResearchMedian progression-free survivalProgression-free survivalMetastatic breast cancerClinical benefitCohort 2Cohort 1FDG-PETWk 8Objective responsePrior linesClinical outcomesMetabolic responseTarget lesionsWk 1Longer progression-free survivalMaximum standardized uptake valuePhase II trialFDG-PET studiesStandardized uptake valueFDG-PET dataFDG-PET imagesEORTC criteriaHypermetabolic uptakeRECIST 1.0II trial